supressor gene
Updated: 2010-02-27 06:50:18
which method used for ACTIVATION FOR BRAIN TUMOUR SUPRESSOR GENE?
cv
Updated: 2010-02-27 06:46:59M. PRABAKARAN 57/31, Bharathiyar Street, West Ambikapuram, Thiruchirapalli – 620 004, Tamilnadu, India. Mob : 9788381384 Email: praba.lifescience@gmail.com Rationale Innovative and productive contribution to the scientific community with a view for human welfare and development. Enthusiastic and willing to expertise in the work arena and reach highest echelons in the concern. Academic Qualification Year In...From Carnivorous Plants to the Medicine Cabinet?
Updated: 2010-02-25 08:52:37In the tropics, carnivorous plants trap unsuspecting prey in a cavity filled with liquid known as a "pitcher". The moment insects like flies, ants and beetles fall into a pitcher, the plant's enzymes are activated and begin dissolving their new meal, obtaining nutrients such as carbon and nitrogen which are difficult to extract from certain soils. Carnivorous plants also possess a highly developed set of compounds and secondary metabolites to aid in their survival........Adjuvant Activity on Human Cells In Vitro
Updated: 2010-02-19 12:39:06Efficient Vacciness against intracellular microbes or tumors will be based on innovative adjuvants able to induce efficient activation of dendritic cells. Indeed, natural or synthetic products activating Toll-like receptors (TLR) on dendritic cells (DCs) are currently in development for this purpose. Herein, we describe in vitro assays on human cells which might be useful for the preclinical screening and assessment of potential DC activators. (Source: Springer protocols feed by Immunology)Nonclinical Safety Assessment of Vacciness and Adjuvants
Updated: 2010-02-19 12:39:06To ensure the safe administration of Vacciness to humans, Vacciness (just like any new chemical entity) are evaluated in a series of nonclinical safety assessment studies that aim at identifying the potential toxicities associated with their administration. The nonclinical safety assessment of Vacciness, however, is only part of a testing battery performed prior to human administration, which includes (1) the evaluation of the Vaccines in efficacy and immunogenicity studies in animal models, (2) a quality control testing program, and (3) toxicology (nonclinical safety assessment) testing in relevant animal models. Although each of these evaluations plays a critical role in ensuring Vaccines safety, the nonclinical safety assessment is the most relevant to the evaluation in human clinical t...Large-Animal Model for Establishing E/T Ratio of Adjuvants
Updated: 2010-02-19 12:39:05To develop novel adjuvants for use in humans, the efficacy/toxicity (E/T) ratio of experimental products in large animal species can be investigated. The test model included two intramuscular immunizations in pigs at 3 weeks interval and analysis of immune responses and local reactions 1 week after the second injection. The antigen used to determine adjuvant activity was a well-defined, purified, viral glycoprotein that without adjuvant induces low immune responses and no detectable local reactions. Efficacy was determined by measuring ELISA and virus-neutralizing antibody titres. Toxicity was determined by necropsy and estimating size and severity of local reactions to each treatment. The persistence of the side effects was deduced from the difference in the local reaction 4 weeks after t...Determining Adjuvant Activity on T-Cell Function In Vivo: Th Cells
Updated: 2010-02-19 12:39:05Adjuvants constitute a critical component in Vaccines development in terms of both stimulating and directing immune responses of a suitable profile to promote protection against a diverse range of disease targets. In the past, the field of adjuvant research was mainly dominated by empirical testing and serendipity. However, there is a strong need to develop new generations of adjuvants based on rational design, as well as a requirement to characterise and comprehend their mechanism(s) of action. Adjuvant development can be characterised as an iterative process where potential candidates are repeatedly tested in vitro and in vivo for immunogenicity and optimised in terms of formulation and delivery. Novel lead candidates of adjuvants with a suitable immunological profile relative to specifi...Functional Antibody Assays
Updated: 2010-02-19 12:39:05Functional antibody assays can broadly be divided into three categories: neutralisation, serum bactericidal antibody (SBA) and opsonophagocytic assays (OPA). These biological assays are generally more complex than antibody-binding counterparts. They invariably involve multiple biological components, many of which are difficult or impossible to standardise. The aim of this chapter is to provide working examples of these assays and highlight the key issues to be addressed to ensure they are able to provide reliable data. (Source: Springer protocols feed by Immunology)Quark Kidney Transplant Drug Receives FDA Orphan Drug Status
Updated: 2010-02-18 13:58:59Search Home News GenomeWeb Daily News BioArray News BioInform In Sequence PCR Insider PGx Reporter ProteoMonitor RNAi News Magazine Blog The Daily Scan Informatics Iron The Sample Careers Job Listings Log in or Register Sunday , February 28, 2010 Arrays Bioregionnews Biotechtransferweek Cbanews DxPGx Informatics PCR Sample Prep Proteomics RNAi Sequencing Home News RNAi News Quark Kidney Transplant Drug Receives FDA Orphan Drug Status February 18, 2010 Type size : Email Printer-friendly version RSS Feed The designation allows for possible research and development incentives , and qualifies the company for tax credits and a period of market exclusivity following market . approval Full-text access for premium subscribers . only Existing premium subscribers login here New to GenomeWeb Register quickly here Related Stories Quark Aims for Five Clinical Indications , New IND in 2010 December 3, 2009 RNAi News Quark Data Shows AMD Drug Reaches Target Cells , Avoids Immune Response May 14, 2009 RNAi News Tekmira Files IND for Hypercholesterolemia Drug with US Regulators April 16, 2009 RNAi News IP Update April 2, 2009 RNAi News Alnylam Begins Phase IIb Study of RSV Therapy February 25, 2010Interview with David J Newman (Pt. II)
Updated: 2010-02-17 13:00:13This is Part II of the unabridged transcript of an interview with Dr David Newman, Chief at the Natural Products Branch of the NCI in Maryland. The interview was conducted for a new quarterly newsletter – Chemistry Matters. You can read Part I in which Dr Newman discussed how natural products can lead to novel [...]Interview with David J Newman (Pt. II) is a post from: Sciencebase Science BlogA natural interview with David Newman
Updated: 2010-02-16 13:00:20David Newman is Chief at the Natural Products Branch, Developmental Therapeutics Program, DCTD, at the National Cancer Institutes in Frederick, Maryland, USA. I interviewed him for Issue 1 of a new quarterly newsletter called Chemistry Matters in Pharma. This is Part I of the unabridged transcript of that interview in which Dr Newman told me of [...]A natural interview with David Newman is a post from: Sciencebase Science Blog4,000 year old genome sequenced
Updated: 2010-02-10 21:49:25An article in the February 11, 2010, issue of Nature describes the sequencing of the complete genome of a 4,000-year old Eskimo (Saqqaq). This is by far the oldest complete genome ever published (only 8 human genomes have been reported so far). The article can be accessed here. What's interesting is the kind of information we can derive about this individual from such data: 1. He was of blood type A+ 2. Had a high likelihood of going bald 3. He had dark hair 4. Had dry e...SSSPG - 2010 Winners Announcement
Updated: 2010-02-10 10:58:19/* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:1...I am collecting the data that those patient treated with traditional medicine
Updated: 2010-02-09 10:14:57today,I tell my really meaning that I told before.the patient that have liver cancer I told is only one example I met.otherwise,that after I will find some another samples.it is of cause that for my theory and reality I want. now I have a another patient that ...Famous paper linking the MMR vaccine to autism retracted
Updated: 2010-02-02 23:14:54The Lancet has retracted the 1998 study linking autism with inoculation against three childhood illnesses, a paper that caused a furor in the research and medicine community and panic and a lasting general backlash against not only the combination MMR vaccination, but childhood immunization programs in general that has still to recover today. Original article http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(97)11096-0/fulltext The retraction of the a...New microarray chip improves drug safety, helps stop animal testing
Updated: 2010-02-02 09:21:47Jonathan West a micro-engineer and his colleagues at the University of Dortmund in Germany, has developed the new microarray chip which can test an estimated 30,000 chemicals their toxicological risk. Called a Network Formation Assay (NFA), the chip lets researchers test compounds faster and more reliably. A normal drug test takes up to 10 hours because [...]FDA launches “Basics” transparency microsite
Updated: 2010-02-02 09:12:44The FDA unveiled phase 1 of its transparency initiative with the launch of FDA Basics, a microsite aimed at demystifying the agency’s workings for the public. It’s the first of a 3 phase transparency initiative launched FDA as part of the Obama Administration’s broader commitment to openness. Phase 2, will deal with disclosure of sensitive information like clinical [...]